A recent study indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional lifestyle plans.
Research printed in a prominent health publication points out that while overweight people frequently drop substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing such treatments must be cognizant of the danger of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight in about one and a half years.
Comparing Therapies
The research, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise usually see a less rapid weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Experts propose the mode of action of the jabs explains the amplified weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the body to produce less of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making overeating far more likely."
A Lifelong Disease?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the high risk of relapse, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who say that the results "underscore the chronic character of obesity," akin to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have stopped the jabs describe a sudden return of appetite.
"I experienced something that goes on and I was suddenly starving," said a patient.
This difficulty is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Significant Interest
Figures suggest that a significant number of adults in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic cure and lasting health benefits relies on integrated behavioural management.
